Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy
SINGAPORE, Apr 10, 2025 – (ACN Newswire via SeaPRwire.com) – April 9, Hebe Biotechnology Pte Ltd (“Hebe Bio”), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD, MBA as Chief Development Officer (CDO), effective April 1, 2025. Dr. Hentze will lead the global development strategy for the company’s next-generation GLP-1 receptor agonist (GLP-1 RA), a cutting-edge weight loss therapy designed to enhance efficacy and tolerability, addressing the global obesity challenge.Strategic Leadership for a Transformative TherapyDr. Hentze brings over two decades of experience in pharmaceutical development, specializing in oncology, metabolic disorders, and biologics. His background spans academic research (IMCB, NTU), biotech ventures (S*BIO, ES Cell International, ASLAN), and large pharmaceutical players (Schering-Plough, MSD). Most recently, he served as Associate Director of Translational Sciences at EDDC (A*STAR).At Hebe Bio, Dr. Hentze will spearhead pr…